Advertisement
Anesthesiology and Pulmonary Medicine
Subscribe to Anesthesiology and Pulmonary Medicine
View Sample

FREE Email Newsletter

New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening

June 5, 2011 5:31 am | by Bio-Medicine.Org | News | Comments

INDIANAPOLIS, June 5, 2011 /- Eli Lilly and Company (NYSE: LLY ) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is...

Mylan Receives Approval for Generic Version of Effexor XR® Capsules

June 2, 2011 9:32 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, June 2, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride (HCl)...

Commencement of GMP Production Project for Lead Anti-Cancer Product PAT-LM1

June 2, 2011 9:32 am | by Bio-Medicine.Org | News | Comments

MELBOURNE, Australia and PRINCETON, N.J., June 2, 2011 /- Patrys Limited (ASX: PAB) (the "Company"), a biopharmaceutical company focused on the development of novel treatments for cancer, is pleased to announce it has extended its relationship with Laureate Biopharmaceutical Services,...

Advertisement

Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase

June 2, 2011 6:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, June 2, 2011 /- Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development. Over the...

Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat

June 2, 2011 5:32 am | by Bio-Medicine.Org | News | Comments

WALTHAM, Mass., June 2, 2011 /- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)-...

Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic

June 2, 2011 3:31 am | by Bio-Medicine.Org | News | Comments

BOULDER, Colo., and PLEASANTON, Calif., June 2, 2011 /- Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The goal is to identify...

Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results

June 1, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin...

Acurest's Custom CPAP Mask Now Available for Sleep Apnea Sufferers in the U.S.

May 31, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

DALLAS, May 31, 2011 /- Acurest, the world's only provider of custom-made Continuous Positive Airway Pressure (CPAP) nasal masks for the treatment of sleep apnea disorder, announced that the solution is now available to sleep apnea sufferers in the U.S. Made specifically for each...

Advertisement

Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer

May 31, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

MALVERN, Pa., May 31, 2011 /- Fujirebio Diagnostics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ EIA assay to monitor disease progression during the course of disease and treatment of lung cancer patients....

Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis

May 26, 2011 10:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 26, 2011 /- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of...

Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference

May 26, 2011 5:31 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., May 26, 2011 /- Masimo (NASDAQ: MASI ) today announced that its management is scheduled to present at the Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in Rancho Palos Verdes, California, on Thursday, June 9, 2011, at 8:40 a.m. Pacific Time.  A...

Nix the Knife

May 26, 2011 5:31 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 26, 2011 /- Patients looking for a quick nip/tuck but don't want to go under the knife now have a way to snap sagging skin into place and outsmart stubborn body fat.  This month, The Body Contouring Center at the renowned JUVA Skin & Laser Center in New York has...

Mylan Launches Generic Version of Roxicodone® Tablets

May 25, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, May 25, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone Hydrochloride (HCI) Tablets USP, 5 mg, 15 mg and 30 mg, based on a development and supply agreement with Coastal Pharmaceuticals. This product is the...

Advertisement

U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care

May 24, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., May 24, 2011 /PRNewswire-USNewswire/ -- Despite significant technological improvements, children reliant on long-term mechanical ventilation often require extensive additional care, including costly hospital stays and emergency visits. A new study led by University of...

$10 Million Verdict Against Johnson & Johnson Unit for Toxic Motrin Reaction, Announces The Jensen Law Firm

May 24, 2011 7:34 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, May 24, 2011 /- Members of Fort Worth, Texas-based Jensen Law Firm ( www.stevensjohnsonsyndrome.org ) are pleased to announce a $10 million verdict in compensatory damages against Johnson & Johnson's McNeil Consumer Products (NYSE: JNJ ) unit on behalf of 13-year-old...

ResMed Announces New iPhone App

May 24, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 24, 2011 /- ResMed (NYSE: RMD ) today released the ResMed Sleep Assessment app, a novel new app for iPhone that lets users record themselves during sleep. The app also includes a clinically validated questionnaire that assesses their risk and other helpful features to...

Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment

May 24, 2011 5:33 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR ), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella...

Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis

May 24, 2011 2:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 24, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis...

Pacira Pharmaceuticals, Inc. Announces EXPARELâ„¢ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting

May 23, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J., May 23, 2011 /- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL™ (bupivacaine extended-release liposome injection) will be presented at the...

Mylan Launches Generic Version of Depakote® Sprinkle Capsules

May 23, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

PITTSBURGH, May 23, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Divalproex Sodium Capsules USP, 125 mg, the generic version of Abbott's Depakote® Sprinkle Capsules, a treatment for certain types of seizures.  ...

A Nightshirt to Monitor Sleep

May 22, 2011 8:33 pm | by Massachusetts Institute of Technology | News | Comments

A newly developed smart shirt detects the wearer's stage of sleep via respiration patterns.

Infinity Pharma: One cancer drug advances, one ends development

May 19, 2011 10:42 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Infinity Pharmaceuticals Inc. is launching a Phase 2 trial of its potential treatment for non-small cell lung cancer, retaspimycin HCl in combination with the approved chemotherapy drug, Taxotere, marketed by French drug maker Sanofi.

Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA

May 19, 2011 5:36 am | by Bio-Medicine.Org | News | Comments

CHICAGO, May 19, 2011 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy announced today that Repligen Corporation has received approval from the U.S. Food and Drug Administration to commence a Phase I safety study in healthy volunteers for RG3039, formerly called...

Takeda to Acquire Nycomed

May 18, 2011 11:37 pm | by Bio-Medicine.Org | News | Comments

OSAKA, Japan, and ZURICH, May 19, 2011 /- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for...

Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD

May 18, 2011 9:41 am | by Bio-Medicine.Org | News | Comments

REDWOOD CITY, Calif., May 18, 2011 /- Pearl Therapeutics Inc. presented detailed efficacy and safety results today from the Company's phase 2b study of PT003  (GFF MDI) in patients with moderate-to-very severe COPD during a late-breaker poster session at the annual meeting of the...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading